2 independently detected trends connected to this subject, with the latest coverage first.
This hub groups 2 separate news trends connected to Rhapsido, spanning September 2, 2026 through September 2, 2026. Each event page combines source coverage, attention velocity and a time-stamped explanation instead of treating every headline as a separate story.
The record below represents 20 article observations and 20 source signals, led by Business coverage. Use it to compare how individual events emerged, spread and changed over time.
Two positive Phase III results for an oral multiple sclerosis drug have pushed Novartis forward in a competitive pharmaceutical market.
Novartis’s Rhapsido clears two Phase III hurdles, sending its stock soaring.